Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.56 |
| ▸ | FLT3 | P36888 | 2/20 | 0.53 |
| ▸ | ULK1 | O75385 | 1/20 | 0.48 |
| ▸ | KIF11 | P52732 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | XDH | P47989 | 2/20 | 0.46 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | GABRP | O00591 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2440393 | 0.96 | HRH4 (0.52) | HRH4FLT3ULK1KIF11CYP1A2 | |
| SCHEMBL6632086 | 0.84 | ALOX5 (0.42) | HRH4FLT3ULK1KIF11ALOX5 | |
| SCHEMBL2204502 | 0.84 | KDM4E (0.55) | HRH4FLT3GLAGAAKDM4E | |
| SCHEMBL3964313 | 0.84 | HRH4 (0.52) | HRH4FLT3CYP1A2KDM4EALDH1A1 | |
| SCHEMBL2134591 | 0.83 | FLT3 (0.58) | FLT3ULK1KIF11CYP1A2GLA | |
| SCHEMBL915460 | 0.83 | HRH4 (0.55) | HRH4FLT3ULK1KIF11CYP1A2 | |
| SCHEMBL30310659 | 0.83 | HRH4 (0.55) | HRH4FLT3ULK1KIF11CYP1A2 | |
| SCHEMBL31414534 | 0.81 | HRH4 (0.56) | HRH4FLT3CYP1A2KDM4EALDH1A1 | |
| SCHEMBL2323348 | 0.81 | FLT3 (0.59) | HRH4FLT3ULK1KIF11CYP1A2 | |
| SCHEMBL217459 | 0.81 | FLT3 (0.66) | HRH4FLT3ULK1GLAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4735422-A1 | SUBSTITUTED CYCLIC COMPOUNDS AND METHODS OF TREATING PHENYLKETONURIA AND OTHER AMINO ACIDURIAS | Sanofi (FR) | 2026-05-06 | — | — | EP | disclosed |
| EP-4587433-A1 | 3-(1H-INDOLE-2-CARBONYL)-6,6-DIMETHYL-N-((S)-1-OXO-3-((S)-2-OXOPYRROLIDIN-3-YL)P ROPAN-2-YL)-3-AZABICYCLO[3.1.0]HEXANE-2-CARBOXAMIDE DERIVATIVES AS MPRO INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | Takeda Pharmaceutical Company Limited (JP) | 2025-07-23 | — | — | EP | disclosed |
| EP-4219460-B1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | SITARI PHARMA INC (US) | 2025-02-26 | — | — | EP | disclosed |
| US-20250011324-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | SITARI PHARMA, INC., | 2025-01-09 | — | — | US | disclosed |
| WO-2025006827-A1 | SUBSTITUTED CYCLIC COMPOUNDS AND METHODS OF TREATING PHENYLKETONURIA AND OTHER AMINO ACIDURIAS | GENZYME CORPORATION (US) | 2025-01-02 | — | — | WO | disclosed |
| US-12152026-B2 | Transglutaminase 2 (TG2) inhibitors | SITARI PHARMA, INC. (US) | 2024-11-26 | — | — | US | disclosed |
| US-12144816-B2 | Substituted indole Mcl-1 inhibitors | VANDERBILT UNIVERSITY (US) | 2024-11-19 | — | — | US | disclosed |
| US-11993571-B2 | Indole derivatives as efflux pump inhibitors | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2024-05-28 | — | — | US | disclosed |
| WO-2024107778-A1 | NOVEL PROTEASE INHIBITORS FOR TREATMENT OF CORONAVIRUS INFECTIONS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-05-23 | — | — | WO | disclosed |
| US-11952365-B2 | Anti-viral compounds | ALIGOS THERAPEUTICS, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| CN-1067988-C | Indoloylguanidine derivatives | SUMITOMO PHARMACEUTICS K K (JP) | 2001-07-04 | — | — | CN | disclosed |
| US-6248772-B1 | HYPOTENSIVE AGENTS; ANTIARRHYTHMIA AGENTS; ANTIDIABETIC AGENTS; ANTIPROLIFERATIVE AGENTS | SUMITOMO PHARMACEUTICALS CO., LTD. (JP) | 2001-06-19 | — | — | US | disclosed |
| US-6169107-B1 | USEFUL FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY INCREASED SODIUM/PROTON (NA.SUP.+ /H.SUP.+) EXCHANGER ACTIVITY, FOR EXAMPLE, HYPERTENSION, ARRHYTHMIA, ANGINA PECTORIS, CARDIAC HYPERTROPHY, DIABETES MELLITUS | SUMITOMO PHARMACEUTICAL CO., LTD. (JP) | 2001-01-02 | — | — | US | disclosed |
| CN-1265108-A | 4-oxo-3,5-dihydro-4H-pyridazino [4,5-b]-indole-1-acetamide derivatives, their prepn. and their application in therapy | SANOFI SYNTHELABO (FR) | 2000-08-30 | — | — | CN | disclosed |
| CN-1051301-C | Indoloylguanidine derivatives | SUMITOMO PHARMA (JP) | 2000-04-12 | — | — | CN | disclosed |
| EP-0622356-B1 | Indoloylguanidine derivatives as inhibitors of sodium-hydrogen exchange | SUMITOMO PHARMA (JP) | 1998-07-01 | — | — | EP | disclosed |
| CN-1136038-A | Indoloylguanidine derivatives | SUMITOMO PHARMACEUTICS K K (JP) | 1996-11-20 | — | — | CN | disclosed |
| EP-0708091-A2 | Indoloylguanidine derivatives | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1996-04-24 | — | — | EP | disclosed |
| CN-1106800-A | Indoloylguanidine derivatives | SUMITOMO PHARMA (JP) | 1995-08-16 | — | — | CN | disclosed |
| EP-0622356-A1 | Indoloylguanidine derivatives as inhibitors of sodium-hydrogen exchange | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1994-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11952365-B2 | Anti-viral compounds | EIF2AK2, ZC3HAV1, HAVCR2 | HRH4 3391/4885FLT3 3680/4885ULK1 2305/4885 |
| US-12152026-B2 | Transglutaminase 2 (TG2) inhibitors | TGM2, TGM3, TGM1 | HRH4 1024/4885FLT3 4708/4885ULK1 1750/4885 |
| US-20250011324-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | TGM2, TGM3, TGM1 | HRH4 1024/4885FLT3 4708/4885ULK1 1750/4885 |
| US-12144816-B2 | Substituted indole Mcl-1 inhibitors | MCL1, BCL2L1, BCL9 | HRH4 4602/4885FLT3 483/4885ULK1 859/4885 |
| US-11993571-B2 | Indole derivatives as efflux pump inhibitors | ABCB11, ABCB1, ABCG2 | HRH4 1903/4885FLT3 4118/4885ULK1 2559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.